News >

Regimen Could Reduce Cardiotoxicity in HER2+ Breast Cancer

Jason Harris
Published: Friday, Sep 28, 2018

Dr. Kelly K. Hunt

Kelly K. Hunt, MD

Women with operable HER2-positive breast cancer had similar long-term survival outcomes with either concurrent or sequential chemotherapy in the neoadjuvant setting, according to newly published results from the phase III ACOSOG Z1041 trial. Combined with previous findings linking the sequential regimen to lower cardiotoxicity, these results suggest this strategy could improve patients’ quality of life.

“Our findings reinforce that approach is unnecessary. Rather, we should save those therapies for patients that don’t achieve complete pathologic remission at surgery and are at high risk of recurrence. Our research needs to focus on a better understanding of the biology of the disease for these patients,” added Buzdar.


  1. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Disease-free and overall survival among patients with operable HER2-positive breast cancer treated with sequential vs concurrent chemotherapy: the ACOSOG Z1041 (Alliance) randomized clinical trial [published online September 6, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.3691.
  2. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(13): 1317–1325. doi: 10.1016/S1470-2045(13)70502-3.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication